美股市场表现 - 纳斯达克综合指数上涨超过300点，涨幅达1.37%至23,521.66点 [1] - 道琼斯工业平均指数上涨0.41%至47,398.49点 [1] - 标普500指数上涨0.82%至6,847.22点 [1] 行业板块表现 - 信息技术股领涨，涨幅达1.5% [1] - 必需消费品股下跌0.3% [2] 个股重大消息 - Keurig Dr Pepper Inc (KDP) 股价大涨约6%，公司第三季度净销售额达到43.1亿美元，同比增长10.7%，超出市场预期的41.5亿美元，并上调了全年销售指引 [3][4] - Sotherly Hotels Inc (SOHO) 股价飙升137%至2.15美元，公司同意被Kemmons Wilson Hospitality Partners附属公司领导的合资企业收购 [10] - Co-Diagnostics Inc (CODX) 股价大涨133%至0.8163美元，公司与Arabian Eagle签署最终协议，在中东地区建立CoMira Diagnostics并本地化其Co-Dx PCR平台 [10] - BIO-key International Inc (BKYI) 股价上涨110%至1.64美元，公司与斯堪的纳维亚主要IT安全分销商IT2Trust建立合作伙伴关系 [10] - Intellia Therapeutics Inc (NTLA) 股价下跌42%至14.92美元，公司宣布暂时停止Nex-z针对转甲状腺素蛋白淀粉样变性心肌病患者的MAGNITUDE和MAGNITUDE-2三期临床研究的患者给药和筛查 [10] - Smart Logistics Global Limited (SLGB) 股价下跌43%至2.93美元 [10] - Genenta Science SpA (GNTA) 股价下跌42%至3.5902美元，公司宣布定价1500万美元的美国存托凭证定向增发 [10] 商品市场 - 原油价格下跌0.1%至每桶61.44美元 [7] - 黄金价格下跌2.1%至每盎司4,051.80美元 [7] - 白银价格下跌2.3%至每盎司47.455美元 [7] - 铜价上涨0.8%至每磅5.1615美元 [7] 全球其他市场 - 欧洲斯托克600指数上涨0.1%，西班牙IBEX 35指数上涨0.6%，英国富时100指数上涨0.1%，德国DAX 40指数下跌0.1%，法国CAC 40指数下跌0.1% [8] - 日本日经225指数上涨2.46%，香港恒生指数上涨1.05%，中国上证综合指数上涨1.18%，印度孟买Sensex指数上涨0.67% [11] 经济数据 - 达拉斯联储制造业指数将于当日发布 [12]

DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the Company welcomes the indicated intention of its largest investor and primary lender, Perceptive Advisors, to submit a proposal that, if implemented, would facilitate the conversion of a portion of the Company’s outstanding debt and other obligations into equity. The Compan ...

Co-Diagnostics, Inc. (NASDAQ:CODX) announced on Monday that it has entered into a joint venture agreement with the Kingdom of Saudi Arabia (KSA) based Arabian Eagle Manufacturing. The agreement aims to research, develop, manufacture, assemble, distribute, and commercialize Co-Dx technologies and intellectual property, including the company's upcoming Co-Dx PCR point-of-care platform in KSA and 18 other countries across the Middle East and North Africa regions. The financial terms of the JV were not disclo ...

FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its TissueCypher® Barrett’s Esophagus test can provide risk insights beyond pathology alone, influencing clinical management to support earlier intervention for those at higher risk of progression to esophageal cancer and potentially reducing unnecessary procedures for those at lower risk. The r ...

This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it is presenting data on its DecisionDx®-Melanoma test and its pipeline atopic dermatitis (AD) gene expression pro ...

Accessibility StatementSkip Navigation SAN DIEGO, Oct. 23, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 52 of its Science Bytes podcast, featuring George Wierschem, MBA, MT(ASCP), Senior Global Product Manager – Informatics. Continue Reading George Wierschem, MBA, MT(ASCP), Senior Global Product Manager – Informatics QuidelOrtho Science Bytes Episode 52: The Power of Informatics in Clinical Decision-Making In the episode titled "T ...

Natera, Inc. Post-ESMO Investor Call October 23, 2025 Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimbursement coverage and our product costs, our commercial and strategic partnerships and potential acquisitio ...

Basel, 23 October 2025 Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and diagnostics.Pharmaceuticals Division sales rose by 9% (4% in CHF) due to continued high growth in sales of medicines for the treatment of severe diseases; Phesgo (breast cancer), Xolair (food allergies), Hemlibra (haemophilia A), Vabysmo (serious eye diseases) and Ocrevus (multiple sclerosis) were the top growth drivers.Diagnostics Divis ...

PresentationLyn ReesCEO & Executive Director Hi, everyone, and welcome to the Novacyt Group Investor Presentation. Over the next few slides, we're going to introduce the presenting team to you, which is just not myself and Steve today. We're going to bring Jo Mason inside the group to talk about our new product introduction and Maria Watters, our new Chief Commercial Officer, to explain the route to market and commercialization strategy. But before we do that, we're going to go through the full year '25 in ...

Accessibility StatementSkip Navigation Conference attendance follows recent MOU announcement for a joint venture with a regional manufacturing and distribution company in the Kingdom of Saudi Arabia SALT LAKE CITY, Oct. 22, 2025 /PRNewswire/ --Â Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that members of the Company's executive leadership team will be in att ...